Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

Kurmasheva, RT; Sammons, M; Favours, E; Wu, J; Kurmashev, D; Cosmopoulos, K; Keilhack, H; Klaus, CR; Houghton, PJ; Smith, MA

Kurmasheva, RT (reprint author), UTHSCSA, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.

PEDIATRIC BLOOD & CANCER, 2017; 64 (3):

Abstract

Background: Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non-Hodgk......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索